Deliver Your News to the World

Quatrefolic® is declared winner of “Most Effective Strategic Product Development” at the Nutraceutical Business & Technology (NBT) Awards.


DESIO, Italy – May, 23rd 2011

Gnosis is the winner of the “Most Effective Strategic Product Development” award at the Nutraceutical Business & Technology (NBT) Awards for the unique and superior folate derivative Quatrefolic®.
Gnosis’ Quatrefolic® was awarded the prestigious first prize from the three top finalists and from a group of 18 candidates during the Gala dinner held in Geneva on May 11th in connection with the Vitafoods Exhibition, the most important event in the world exclusively focused on the expanding market for nutraceuticals, functional foods and drinks, ingredients & raw materials.

The independent and impartial expert judging panel recognized Gnosis and its new compound Quatrefolic®, for excellence in; innovative patent design, high quality product development, flexibility and choice for the consumer, recognizing market and consumer demands and trends, strategic market orientation, project planning and execution and overcoming research and development challenges.
Quatrefolic® is a new generation of folate derivative with benefits over the older generation (6S)-5-methyltetrahydrofolate calcium salt.

Quatrefolic® highlights

1- Manufactured under cGMP
2- Greater bioavailability than the 5-methytetrahydrofolate calcium salt form
3- Able to penetrate cells without being metabolized
4- Greater solubility to facilitate improved formulating flexibility
5- Greater stability to facilitate improved formulating flexibility
6- Ability to formulate in combination with vitamins and minerals
7- Proprietary (patents granted)
8- Trademark registered
9- GRAS status
10- NDIN recognition

After a screening of several molecules Gnosis’ research team identify Glucosamine as a new salt of the biologically active form of folate (6S)-5-methyltetrahydrofolate with superior properties, showing a solubility 100 times more than calcium salt and an improved bioavailability of the new dietary ingredient. Stability of product has been performed according to ICH guidelines supporting long lasting chemical stability at room temperature ensuring easy handling and storage and improved formulating flexibility.
GRAS (generally recognized as safe) status has been achieved for use in conventional and medical foods.
Finally he Food and Drug Administration (FDA) has recognized Quatrefolic® as a New Dietary Ingredient (NDI) in November 2010.

“We are very honoured to receive this award that reinforces our belief that Quatrefolic®, the 4th generation of folate, will represent a real award for the final consumer”, commented Paolo Malesani, Gnosis’ Commercial Director upon receiving the award and recognition.

Gnosis has protected Quatrefolic® Intellectual Property by two international patent applications, about the new chemical entity and the process to obtain it. The patents cover combination of the innovative folate derivative with vitamins and minerals, allowing the marketers of Quatrefolic® to mix the ingredient with their existing combinations and formulations without violating any existing patent guaranteeing an incremental innovation program of the actual range of applications including medical foods, dietary supplements as well as food and beverage finished products.

For more information visit
For inquiries related to North American market, contact:

For the rest of the world, please contact:


 NBT Awards

This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.